Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap. Based on the Aldeyra The stock forecasts from 5 analysts, the average analyst target price for Aldeyra The is USD 19.67 over the next 12 months. Aldeyra The’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aldeyra The is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Aldeyra The’s stock price was USD 3.86. Aldeyra The’s stock price has changed by +26.14% over the past week, +56.28% over the past month and -69.29% over the last year.

1. Page 1 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ALDX:NSD (Aldeyra The)
Biotechnology | NSD | Common Stock
Values as of 9th Jun, 2022
Stock Target Advisor
Detailed Stock Report
Report Date: 10th June, 2022
Last Close
USD 3.86
Change
+0.36(+10.29%)
Market Cap
USD 0.20B
1 Yr Capital Gain
-68.90%
1 Yr Dividend Return
N/A
1 Yr Total Return
-68.90%
Earning Growth (5 yr)
-308,873.12%
Average Target Price
19.67(+409.50% )
Average Analyst
Rating
Strong Buy
Fundamental
Analysis
Bearish
Our view of the stock is Bearish with a score of 2.5 out of 10, where 0 is very bearish and 10 very bullish
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What to not like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector

2. Page 2 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ALDX:NSD (Aldeyra The)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 10th June, 2022
Adjusted Closing Share Volume
Relative Returns Relative Performance (Total Returns)
Security Capital Gain Dividend Return Total Return
ALDX
Aldeyra The
-69.3% 0 -69.3%
QQQ
Invesco QQQ Trust
-11.1% +0.4% -10.7%
Company Overview
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic
diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical
trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP
modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in
phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for
treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing
ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa
Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004
and is based in Lexington, Massachusetts. Address: 131 Hartwell Avenue, Lexington, MA, United States, 02421

3. Page 3 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Company Website
https://www.aldeyra.com
Address
131 Hartwell Avenue, Lexington, MA, United States, 02421
Fiscal Year End
December
Employees
14
Technical Indicators
Value Value
Beta 1.64 52 Week High 12.54
Short Ratio 3.55 52 Week Low 2.36
Shorted Shares 2,900,665 200 Day Moving Average 5.66
Shorted Shares Previous Month 2,908,423 50 Day Moving Average 3.47
Shares Held By Insiders 146.10% Short Percentage 6.00%
Shares Held by Institutions 65.92 Dividend Yield N/A

4. Page 4 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ALDX:NSD (Aldeyra The)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 10th June, 2022
Market Performance
Market Performance vs. Industry / Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
YTD
Capital Gain -3.50% -43.0% 90% -18.3% 71%
Dividend Return N/A 1.0% N/A 1.0% N/A
Total Return -3.50% -43.0% 90% -17.9% 70%
Trailing 12 Months
Capital Gain -68.90% -66.5% 46% -22.1% 22%
Dividend Return N/A 1.5% N/A 2.3% N/A
Total Return -68.90% -66.5% 46% -21.1% 22%
Trailing 5 Years
Capital Gain -23.56% -58.4% 65% 3.6% 32%
Dividend Return N/A 13.9% N/A 10.9% N/A
Total Return -23.56% -55.9% 65% 14.1% 28%
Average Annual (5 Year Horizon)
Capital Gain 26.42% 2.9% 72% 2.3% 80%
Dividend Return N/A 9.4% N/A 1.8% N/A
Total Return 26.42% 3.9% 71% 4.2% 80%
Risk Return Profile
Volatility (Standard
Deviation)
100.47% 58.3% 24% 32.2% 13%
Risk Adjusted Return 26.30% N/A 67% 20.5% 56%
Market Capitalization 0.20B 0.13B 59% 0.32B 40%

5. Page 5 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Key Financial Ratios
Ratios vs. Industry / Classification (Computer Hardware) Ratios vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
Market Value
peratio N/A 7.9 N/A 17.0 N/A
pbratio 0.9 1.8 74% 1.6 81%
pcfratio 0.0 -2.6 10% -0.1 49%
pfcfratio 0.6 0.6 54% 10.0 87%
Management Effectiveness
retequity -39.95% -57.0% 68% 0.3% 27%
retinvcap -38.01% -54.2% 67% -0.6% 25%
retass -20.90% -26.2% 63% 0.1% 20%
debtequityratio 7.54% 20.7% 69% 32.1% 76%
Technical Ratios
yield N/A 1.9% N/A 2.6% N/A
sratio 3.55 4.81 61% 3.11 45%
spercent 6.12% 5.0% 42% 2.9% 29%
beta 1.64 1.41 34% 1.10 21%

6. Page 6 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ALDX:NSD (Aldeyra The)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 10th June, 2022
Recent Analyst Ratings
Price Action Rating Action Analyst Rating Price date
Maintains Citigroup Buy USD 21 » USD 26 2022-06-09
Target Up Oppenheimer Holdings USD 11 2022-06-09
Target Up Jones Trading USD 17 2022-06-09
Initiated by Berenberg Capital Markets Buy USD 28 2022-05-24
Maintains SVB Leerink Outperform USD 24 » USD 15 2021-12-21
Maintains Citigroup Buy USD 25 » USD 21 2021-12-21
Reiterated by SVB Leerink Buy USD 24 2021-12-01
Target Raised by Citigroup USD 22 » USD 25 2021-04-28
Reiterated by SVB Leerink Buy USD 22 2021-04-25
Initiates Coverage On SVB Leerink Outperform USD 22 2021-03-12
Initiated by HC Wainwright Buy USD 26 2021-02-08
Initiated by Berenberg Capital Markets Buy USD 32 2020-12-16
Initiates Coverage On Jefferies Financial LLC Buy USD 24 2020-10-30
Initiated by Alliance Global Partners Buy USD 32 2020-09-22
Target Lowered by Citigroup Buy USD 24 » USD 22 2020-08-11
Reiterated by Oppenheimer Holdings Buy USD 15 2020-08-07
Initiates Coverage On Oppenheimer Holdings Outperform USD 12 2020-05-12
Initiated by Oppenheimer Holdings Outperform 2020-05-11
Assumes Cantor Fitzgerald Securities Overweight USD 33 2019-10-22
Reiterates Cantor Fitzgerald Securities Buy USD 30 » USD 35 2019-03-26
Reiterates Citigroup Buy » Positive USD 32 » USD 38 2019-03-26
Set Price Target Cantor Fitzgerald Securities Buy USD 30 2019-01-29
Initiates Citigroup Buy » Buy USD 23 2018-12-04
Set Price Target Cantor Fitzgerald Securities Buy USD 30 2018-11-14
Set Price Target Cantor Fitzgerald Securities Buy USD 30 2018-10-04

7. Page 7 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ALDX:NSD (Aldeyra The)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 10th June, 2022
Annual Financial (USD)

8. Page 8 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ALDX:NSD (Aldeyra The)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 10th June, 2022
Quarterly Financial (USD)

9. Page 9 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ALDX:NSD (Aldeyra The)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 10th June, 2022
Largest Industry Peers for Biotechnology
Symbol Company Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc -14.84 (-5.4%) USD 70.22B
REGN Regeneron Pharmaceuticals Inc -32.28 (-5.3%) USD 66.76B
MRNA Moderna Inc -14.49 (-9.8%) USD 57.81B
ALXN Alexion Pharmaceuticals Inc N/A USD 40.34B
BNTX BioNTech SE -12.46 (-7.7%) USD 38.91B
RPRX Royalty Pharma plc -0.41 (-1.0%) USD 27.86B
SGEN Seagen Inc -2.54 (-1.8%) USD 26.56B
IMMU Immunomedics, Inc N/A USD 20.31B
GMAB Genmab AS -1.27 (-4.1%) USD 20.15B
BGNE BeiGene Ltd -11.41 (-7.0%) USD 18.09B
The Stock Target Advisor platform run millions of calculations every day on over 30,000 Canadian and American stocks, comparing and
ranking their financial and market performance against their sectors and exchange.
We represent the percentile ranking using the following grading system.
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%